Biomay

Biomay is a well-established, Vienna-based CDMO with over two decades of experience in GMP manufacturing of biologics, particularly plasmid DNA. It has successfully pivoted and expanded its technology platform to become a key player in the mRNA and advanced therapy medicinal product (ATMP) manufacturing space, evidenced by recent FDA approvals and strategic partnerships. The company operates as a 'one-stop' manufacturer, providing integrated services from template DNA through to aseptic fill-finish, catering to the burgeoning cell and gene therapy market. Its recent product launches, such as off-the-shelf Cas9 mRNA and nucleases, position it as both a service provider and a critical reagent supplier.

Integrated GMP manufacturing platform for plasmid DNA, mRNA (including in-vitro transcription and lipid-nanoparticle formulation), and recombinant proteins. Offers end-to-end services from gene construction to aseptic fill-finish.

Biomay competes in a crowded global CDMO market against giants like Lonza and Catalent, as well as specialized peers in mRNA (e.g., eTheRNA, Aldevron) and gene therapy manufacturing. Its differentiation lies in its integrated 'one-stop' offering for pDNA, mRNA, and proteins, its deep historical expertise, and its strategic focus on off-the-shelf GMP reagents for high-demand applications like CRISPR.